<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289067</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1222</org_study_id>
    <secondary_id>Prostate Cancer Foundation</secondary_id>
    <nct_id>NCT01289067</nct_id>
  </id_info>
  <brief_title>Utilizing A Genomic Sig for &quot;BRCAness&quot; to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca</brief_title>
  <official_title>Predicting Response to Platinum Chemotherapy in Metastatic Castration Resistant Prostate Ca(mCRPC)Using a Genomic Signature for &quot;BRCAness&quot;: A Phase II Prospective Open Label Clinical Trial of Satraplatin in Men With mCRPC Who Have Progressed on Docetaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William K. Oh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostate Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test genes for BRCAness(BRCA[BReast CAncer] gene) Studying
      these genes could help predict which patients would benefit from treatment with satraplatin,
      a medication being used for subjects who have failed prior chemotherapy. All subjects will
      have a biopsy of metastatic lesions to measure BRCAness (a gene signature). This gene
      signature may be able to predict response to satraplatin and a tool will be developed to be
      able to screen patients likely to benefit from satraplatin. Subjects will all receive
      Satraplatin days 1-5 and Prednisone 5 mg twice daily every 35 days. Response rates will be
      evaluated every 2 cycles or approximately every 9 weeks. Patients will be considered
      responders if they have measurable disease meeting criteria for partial or complete response.
      PSA will be measured day one of each treatment cycle. Each treatment cycle is 35 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be developing a genomic based signature of &quot;BRCAness&quot; based on literature of genomic
      signatures from women with breast cancer and germline BRCA mutations.The &quot;BRCAness&quot; breast
      cancer signature will differentiate germline BRCA 1/2 breast cancers from standard
      estrogen-receptor (+) breast cancers. We will obtain a library of genomic signatures Recently
      these techniques have been used to develop a transcriptional &quot;signature&quot; for androgen
      receptor (AR) activity in men with CRPC(Castration Resistant Prostate Cancer). The
      investigator will apply the &quot;BRCAness&quot; breast cancer signature to pathological prostate
      cancer specimens to determine the percentage of patients in the overall prostate cancer
      population that express this signature, as well as the clinical and histological phenotype of
      this population.

      This novel prostate cancer &quot;BRCAness&quot; signature will be developed over a period of 4-6
      months. This &quot;BRCAness&quot; signature has not previously been evaluated in prostate cancer
      patients and would be expected, based on known characteristics of BRCA mutant breast and
      ovarian cancers, to be more platinum-responsive. Relevant clinical data, including histology,
      grade, stage, size of residual tumor, recurrence, and survival, will be obtained from
      outpatient and inpatient charts to perform subsequent correlative studies.

      All patients enrolled in the phase II clinical trial with satraplatin will have pre-treatment
      biopsies of metastatic sites. All of the specimens will be frozen, batched and stored as
      previously described. We anticipate that all patients will be enrolled 16 months from when
      the trial opens. When the last patient is enrolled in the trial and all of the metastatic
      biopsies have been collected, they will be shipped in bulk on dry ice to laboratory for
      RNA(ribonucleic acid) isolation, RNA quality assessment and processing, microarray
      hybridization, microarray data quality assessment, and &quot;BRCAness&quot; prostate cancer signature
      application. Frozen biopsies will be processed for microarray analysis using laser capture
      microdissection and RNA amplification using adaptations of previously published methods. The
      application of the prostate cancer BRCAness signature will take place over two months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Satraplatin as Second Line Therapy in Men With CRCP</measure>
    <time_frame>3 months</time_frame>
    <description>Patients with good tolerance of treatment who have a 30% PSA decline from their pre-treatment level within 3 months of treatment initiation will be considered responders provided objective tumor measurements are stable or also demonstrate response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Maximum Decline in PSA</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Response rate - Maximum decline in PSA that occurs during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression Free Survival is measured from the time of the initiation of therapy until the first date that recurrent or progressive disease is objectively documented. Progression is a composite endpoint that can be based upon PSA, objective measures of disease, symptoms or death. Time to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Patients followed for a minimum of 24 months or until death. Patients and/or their family members will be contacted via telephone calls or certified letter.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Satraplatin, Single Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satraplatin</intervention_name>
    <description>Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
    <arm_group_label>Satraplatin, Single Arm</arm_group_label>
    <other_name>JM-118</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed adenocarcinoma of the prostate.

          2. Radiographic evidence of metastatic disease (Bone scan, CT(Computerized Tomography)
             scan, or MRI(Magnetic Resonance Imaging) are acceptable) amenable to image-guided
             biopsy.

          3. Castrate levels of testosterone (testosterone &lt;50 ng/dL) on androgen deprivation
             therapy (ADT). LHRH(luteinizing hormone releasing hormone)agonist therapy must
             continue while on study unless patient has previously undergone an orchiectomy.

          4. The patient must have discontinued antiandrogens (bicalutamide, flutamide or
             nilutamide) 30 days prior to baseline PSA.

          5. Progression on at least one line of a prior docetaxel-based chemotherapy.

          6. Patients must have adequate organ and marrow function as defined below:

               -  Absolute neutrophil count &gt;1,500/μl

               -  Platelets &gt;100,000/μl

               -  GFR(glomerular Filtration Rate) &gt;30 ml/min

               -  ALT(Alanine transaminase) and AST(Aspartate transaminase) ≤ 2.5 X upper limit of
                  normal (ULN) or ≤ 5 X ULN in patients with liver metastasis

          7. Age &gt; 18 years

          8. Ability to take oral medications (pills must be swallowed whole)

          9. ECOG (Eastern Cooperative Oncology Group) performance status 0-2

         10. Ability to understand and the willingness to sign a written informed consent document

         11. Patients must be willing to undergo an image-guided biopsy of a metastatic site on at
             least one occasion.

         12. Patient agrees to utilize contraception while enrolled in the trial

        Exclusion Criteria:

          1. Patients who have received prior treatment with a platinum chemotherapy.

          2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection (requiring antifungal, antibiotic or antiviral therapy), history of
             symptomatic congestive heart failure (NYHC (New York Heart Association Classification)
             III), unstable angina pectoris, cardiac arrhythmia (uncontrolled SVT(Super ventricular
             tachycardia)or any VT(ventricular tachycardia), or psychiatric illness/social
             situations that would limit compliance with study requirements.

          3. Patients with a medical contraindication to image-guided biopsies

          4. Patients with a severe allergic reaction to satraplatin compounds.

          5. Has a history of a prior malignancy with the exception of the following: adequately
             treated basal cell or squamous cell skin cancer, or other cancers for which the
             subject has been disease-free for at least 5 years.

          6. Has had radiation therapy within 30 days prior to being registered for protocol
             therapy.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William K Oh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <results_first_submitted>January 10, 2017</results_first_submitted>
  <results_first_submitted_qc>January 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>William K. Oh</investigator_full_name>
    <investigator_title>Chief, Division of Hematology/Medical Oncology</investigator_title>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Castration Resistant</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Satraplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in December 2010. Thirteen (13) patients from Mount Sinai Medical Center were enrolled to the study between January 27, 2011 and March 7, 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Satraplatin, Single Arm</title>
          <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Satraplatin, Single Arm</title>
          <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="54" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metastasis site</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bone only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone and Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone and Visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node and Visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone, Lymph Node, and Visceral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason Score</title>
          <description>Gleason scores range from 2 to 10, with 2 representing the most well-differentiated tumors and 10 the least-differentiated tumors. Least-differentiated tumors typically have a worse prognosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gleason 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gleason 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA</title>
          <description>pre-treatment PSA</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.67" lower_limit="0.04" upper_limit="3057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Satraplatin as Second Line Therapy in Men With CRCP</title>
        <description>Patients with good tolerance of treatment who have a 30% PSA decline from their pre-treatment level within 3 months of treatment initiation will be considered responders provided objective tumor measurements are stable or also demonstrate response.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin, Single Arm</title>
            <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Satraplatin as Second Line Therapy in Men With CRCP</title>
          <description>Patients with good tolerance of treatment who have a 30% PSA decline from their pre-treatment level within 3 months of treatment initiation will be considered responders provided objective tumor measurements are stable or also demonstrate response.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not evaluable for response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Maximum Decline in PSA</title>
        <description>Response rate - Maximum decline in PSA that occurs during treatment.</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>Only responders included</population>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin, Single Arm</title>
            <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days to Maximum Decline in PSA</title>
          <description>Response rate - Maximum decline in PSA that occurs during treatment.</description>
          <population>Only responders included</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.5" lower_limit="68" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression Free Survival is measured from the time of the initiation of therapy until the first date that recurrent or progressive disease is objectively documented. Progression is a composite endpoint that can be based upon PSA, objective measures of disease, symptoms or death. Time to disease progression.</description>
        <time_frame>up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin, Single Arm</title>
            <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression Free Survival is measured from the time of the initiation of therapy until the first date that recurrent or progressive disease is objectively documented. Progression is a composite endpoint that can be based upon PSA, objective measures of disease, symptoms or death. Time to disease progression.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" lower_limit="73" upper_limit="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonresponders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="31" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Patients followed for a minimum of 24 months or until death. Patients and/or their family members will be contacted via telephone calls or certified letter.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin, Single Arm</title>
            <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Patients followed for a minimum of 24 months or until death. Patients and/or their family members will be contacted via telephone calls or certified letter.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="570" lower_limit="184" upper_limit="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonresponders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486" lower_limit="147" upper_limit="644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Satraplatin, Single Arm</title>
          <description>Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thromboscytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>limitation include low sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Bobby Liaw</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>(212) 604-6010</phone>
      <email>bobby.liaw@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

